Navigation Links
Archimedes Pharma Announces Publication of Long-Term Safety and Tolerability Clinical Study of Fentanyl Pectin Nasal Spray (FPNS) in the Journal of Opioid Management
Date:10/12/2010

READING, England and BEDMINSTER, N.J., Oct. 12 /PRNewswire/ -- Archimedes Pharma, an emerging specialty pharma company focused on oncology, pain, neurology and critical care sectors, today announced publication of results from a Phase III, long-term safety, tolerability and consistency of effect, clinical study of fentanyl pectin nasal spray (FPNS) in the treatment of breakthrough cancer pain (BTCP).

The article, entitled "Long-term safety, tolerability, and consistency of effect of fentanyl pectin nasal spray for breakthrough cancer pain in opioid-tolerant patients," [fentanyl pectin nasal spray is called PecFent® in Europe] has been published in the September/October issue of the Journal of Opioid Management.  The Phase III multicenter open-label study analyzed 403 adult cancer patients and was conducted in 91 centers over 16 weeks.  FPNS was self-administered for 42,227 episodes of BTCP.  The study assessed the long-term safety, tolerability, and consistency of FPNS effectiveness and dose in adult cancer patients with BTCP. The abstract of the study is available at: http://bit.ly/a8ptCF.

This study demonstrated that FPNS was acceptable and generally well tolerated in patients suffering from breakthrough cancer pain. In this trial the most frequently reported adverse events were typical of opioid medications and included dizziness, vomiting, constipation and somnolence. Nasal tolerability of FPNS over the long term was demonstrated as good with no significant nasal adverse events.  94% of BTCP episodes were successfully treated by a single dose of FPNS and did not require additional rescue medication within 60 minutes of FPNS treatment. In addition, more than 90% of patients required no increase in their dose of FPNS, once titration was achieved.

Jeff Buchalter, President and CEO of Archimedes Pharma, commented, "The long-term usage data continues to support FPNS as a highly acceptable and consistently effective product for the long-term treatment of BTCP."  He continued, "With our recent launch of PecFent® in the UK and upcoming launches in additional European countries, Archimedes Pharma is providing a new therapy to improve the treatment options for adult patients with breakthrough cancer pain.  An NDA has been submitted with the US Food and Drug Administration and is currently under review."

Notes to editors:About Archimedes PharmaArchimedes Pharma is an international specialty pharmaceutical company focused on the oncology, pain, neurology, and critical care sectors. Archimedes Pharma is marketing an expanding portfolio of specialist products to hospital-based prescribers in Europe and has established commercial organizations in the UK, US, France, Germany, Ireland, and Spain.

Fentanyl Pectin Nasal Spray [called PecFent® in Europe]

PecFent is an innovative fentanyl pectin citrate nasal spray that has been granted Marketing Authorization by the European Medicines Agency for the treatment of breakthrough cancer pain in adults who are already receiving maintenance opioid therapy for chronic cancer pain.  It is under review by the US Food and Drug Administration (FDA).

In the clinical trial program, the use of PecFent in the treatment of breakthrough cancer pain was associated with the occurrence of adverse events typical of opioid medication in this population.  The most frequently reported were vomiting, nausea, disease progression and constipation.  The majority of such events were mild to moderate in intensity, and adverse effects assessed as treatment-related led to study withdrawal in 3.9% of patients.

About Breakthrough Cancer Pain (BTCP)

Breakthrough cancer pain affects 24% to 95% (average across all studies 62%) of all cancer patients with pain and is characterized by sudden, often unpredictable episodes of intense pain that occur despite background pain medication. This pain is rapid in onset, usually reaching maximum intensity in five minutes and lasting for 30 to 60 minutes.

For more information, please visit: www.archimedespharma.com.Media contacts:Tiberend Strategic Advisors, Inc. (USA)Tamara Bright +1 212-827-0020 tbright@tiberendstrategicadvisors.com Citigate Dewe Rogerson (UK and Europe)Chris Gardner +44 207 638 9571 chris.gardner@citigatedr.co.uk
'/>"/>

SOURCE Archimedes Pharma
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Archimedes Pharma Announces Publication of a Pivotal Clinical Study of Fentanyl Pectin Nasal Spray (FPNS) in Pain, the Peer-Reviewed Journal from the International Association for the Study of Pain
2. Archimedes Pharma Receives CHMP Positive Opinion for PecFent(R) for the Treatment of Breakthrough Cancer Pain
3. Archimedes Pharma Announces Successful Proof-of-Concept Results on Two Intranasal Development Projects
4. Auxilium Pharmaceuticals, Inc. Announces Issuance of Patent for Clostridial Collagenase
5. Cranewares Pharmacy ChargeLink® Version 3 Helps Improve Margins and Control Costs
6. Johnson & Johnson to Host Analyst Meeting to Discuss Third-Quarter Financial Results and Review Pharmaceutical Business
7. Generex Reaches Agreement to Acquire 51% Stake in Global Medical Direct, a Nationwide Durable Medical Equipment and Pharmaceutical Provider Specializing in Direct-to-Consumer Diabetes Supplies
8. Newly Revised Concepts in Clinical Pharmacokinetics Web-Based Continuing Education Course Offered by the University of Georgia
9. Webcast Alert: CEL-SCI Corp. (CVM) Announces the Biotech, Healthcare and Pharma Virtual Conference
10. PharmaNet Development Group Announces Observational Research Survey
11. Jazz Pharmaceuticals Receives FDA Complete Response Letter Regarding JZP-6 for Treatment of Fibromyalgia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... Centers for Disease Control and Prevention (CDC), influenza vaccination should take ... communities across Massachusetts , Connecticut , ... through the end of the month. *Some exclusions apply ... ... by the end of October, according to the Centers for Disease Control ...
(Date:10/2/2017)... 2017  AllianceRx Walgreens Prime, the combined central specialty ... pharmacy benefit manager Prime Therapeutics LLC (Prime), today officially ... the unveiling of new signage at its headquarters in ... at a few other company-owned facilities across the country. ... some of whom will begin to see the AllianceRx ...
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans ... advance the use of wearable and home sensors for ... disorders. Early Signal Foundation, a nonprofit organization focused on ... will provide an affordable analytical system to record and ... ...
Breaking Medicine Technology:
(Date:10/12/2017)... CA (PRWEB) , ... October 12, 2017 , ... ... Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent technology. ... a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... introduction of an innovative new design of the shoulder pad. The shoulder pad ... comfort while controlling your pain while using cold therapy. By utilizing ice and water ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
(Date:10/12/2017)... D.C. (PRWEB) , ... October 12, 2017 , ... Leading ... their peers in Washington, D.C., for the 49th Congress of the International Society ... ., Vice President of the Center for Cancer and Blood Disorders at ...
(Date:10/12/2017)... ... , ... Health Literacy Innovations (HLI), creator of the Health ... Cancer Patient Education Network (CPEN), an independent professional organization that shares best practices ... , As CPEN’s strategic partner, HLI will help support CPEN members by ...
Breaking Medicine News(10 mins):